Abstract: The present invention relates to the use of D-beta-hydroxybutyrate (D-BHB) in the treatment or dietary management of a Long-Chain Fatty Acid Oxidation Deficiency (LC-FAOD), for example, in the prevention and/or amelioration of one or more symptoms associated with LC-FOAD. Additionally, the invention provides compositions comprising D-BHB as the active ingredient. These compositions may be formulated as pharmaceutical compositions or nutritional compositions, such as Foods for Special Medical Purposes (FSMPs).

Abstract: The present invention relates to the use of D-beta-hydroxybutyrate (D-BHB) in the treatment or dietary management of multiple acyl-CoA dehydrogenase deficiency (MADD), for example, in the prevention and/or amelioration of one or more symptoms associated with MADD. Further provided herein are methods of treatment or dietary managements of MADD in a subject in need, comprising administering to said subject a composition comprising D-BHB as the active ingredient.

Abstract: The invention provides novel methods for isolating, characterizing, comparing, and using biological components that are present in the cerebrospinal fluid. Such biological structures, called CS-MPs, can be used for identifying biomarkers that reflect the status (or anticipate the development) of disorders of the Central nervous System (CNS). The novel methods, biological products, and related kits make possible the use of CS-MPs and of their components as biomarkers for the diagnosis, prognosis, or monitoring of CNS disorders. The CS-MPs have a diameter comprised between 100 and 1000 nm and contain phosphatidylserine (PS).

Abstract: The present invention concerns a method for identifying substances useful for treating inflammation, characterized in that it comprises the following steps: (a) placing said substance in contact with a nucleic acid construct containing the Retinoid-Related Orphan Receptor (ROR) receptor response element of the promoter of the I?B? gene, under conditions suitable for allowing said substance to bind to said response element, (b) measuring the possible binding of said substance to the response element or the transcriptional activity of the response element or of a promoter containing it, (c) optionally comparing the measurement of step (b) with a measurement carried out under conditions similar to those of steps (a) and (b) but with a nucleic acid construct containing the mutated response element.

Abstract: Methods or prevention or treatment of diseases or conditions caused by low plasma apoA-1 levels, the use of LRH1 activators in such methods and methods for identification of compounds useful in such treatment.

Abstract: The present invention concerns a method for identifying substances useful for treating inflammation, characterized in that it comprises the following steps: (a) placing said substance in contact with a nucleic acid construct containing the ROR receptor response element of the promoter of the I?B? gene, under conditions suitable for allowing said substance to bind to said response element, (b) measuring the possible binding of said substance to the response element or the transcriptional activity of the response element or of a promoter containing it, (c) optionally comparing the measurement of step (b) with a measurement carried out under conditions similar to those of steps (a) and (b) but with a nucleic acid construct containing the mutated response element.